Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors Dec 02, 2020 8:30am EST
Artelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs Nov 23, 2020 8:30am EST
Artelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss Nov 16, 2020 8:30am EST
Artelo Biosciences to Present at the Virtual Fall Investor Summit on November 18th Nov 11, 2020 8:30am EST
Artelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update Nov 04, 2020 8:00am EST
Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders Oct 21, 2020 8:30am EDT
Artelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option Oct 14, 2020 4:05pm EDT
Artelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering Oct 09, 2020 8:30am EDT
Artelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia Sep 29, 2020 8:00am EDT
Artelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th Sep 11, 2020 9:00am EDT
